ChatGPt
In the context of cancer therapy companies and the National Institute for Health and Care Excellence (NICE) in the UK, the process typically involves companies submitting evidence for the evaluation of new therapies to NICE. This evidence is used to inform decision-making regarding the clinical and cost-effectiveness of the therapy.
The timing of the evidence submission can vary depending on the specific circumstances and the regulatory process. In some cases, companies may submit evidence to NICE during the marketing approval process, while in other cases, they may wait until after marketing approval has been obtained. It is important to note that the submission of evidence to NICE is a separate process from obtaining marketing approval.
The decision on when to submit evidence to NICE can depend on various factors, including the availability of clinical trial data, regulatory requirements, and strategic considerations of the company. It is essential for companies to engage with NICE early in the development process to ensure that the necessary evidence is generated and submitted in a timely manner.
It is recommended that companies consult with regulatory and reimbursement agencies, such as NICE, throughout the drug development process to understand the specific requirements and timelines for evidence submission.
Market Data 
Markets 
